Companies and Markets
Call us on +44 (0) 203 086 8600
Market Research A to Z | Company Profiles A to Z | RegisterRegister | Contact UsContact Us | Shopping Basket Shopping Basket
+44 (0) 203 086 8600 Call us on

Downstream Processing in Biopharmaceuticals

2169.71

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

Site License

Site License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.

Corporate License

Corporate License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£2,169.71

Change Currency

GBP EURO USD
GBP EURO USD

Market

Healthcare and Medical

Report Type

Market Research

Country

Global

Published

1 November 2012

Number of Pages

59

Report Delivery

Email

Delivery Lead Time

1-3 hours, 24 hour max

Publisher

GBI Research

File Format

PDF

Global CMO market to hit value of $59.9 billion by 2018

Global contract manufacturing organizations (CMOs) are set to steadily become more and more popular, as Western pharmaceutical companies outsource production to Asian countries in a bid to cut costs. Overall cost of drug manufacturing is up to 50% cheaper in India than in Western countries, which is pushing Big-Pharma abroad.

Major CMOs offer upstream and downstream manufacturing functions equally; and, in addition to manufacturing in biopharmaceutical production, they also offer clinical trials, logistics, packaging, and even marketing. According to the industry experts, manufacturing functions dominate almost 60% of the CMO market, with downstream processes accounting for 50% of the manufacturing process.

The CMO market size for downstream processing is set to grow at a CAGR of 15.1%, which is higher than the growth of the overall CMO biopharmaceutical market, due to the approval of biosimilars in the downstream industry, which is expected to drastically increasing future demand for equipment and reagents.

In spite of high drug prices, biopharmaceutical firms are not currently able to fulfil high market demand, and once these prices come down, demand will grow at a much faster rate. The increased use of disposables in biopharmaceutical manufacturing is also boosting the downstream market, as reductions in capital and cleaning costs for pharmaceutical companies turn profits for CMOs.

CMOs are working to integrate service portfolios in order to offer complete solutions to pharmaceutical manufacturers. While the concept of providing total biopharmaceutical solutions has historically been present only within the US and certain European countries, nations such as India, Korea and China have started to adopt the same business model over the past few years, and have attracted big business as a result, thanks to vast differences in production and labor costs in developed and developing countries. These forged relationships allow both CMOs and pharmaceutical manufacturers to pursue large-scale business opportunities using each others facilities.

We suggest that the global CMO market is set to grow steadily, due to increasing levels of pharmaceutical outsourcing and generic manufacturing. The global CMO market grew at around 10.8%, from $21.2 billion in 2008 to $28.8 billion in 2011, and is forecast to reach an approximate value of $59.9 billion by 2018 following growth at a CAGR of 11%.

Report Overview

This report provides key data, information and analysis of the Contract Manufacturing Organization (CMO) industry, and the downstream processing and reagent market. The report provides comprehensive insight into the size of the CMO market, the downstream processing and reagent market and includes forecasts, key reasons for outsourcing, market characterization, downstream process in biopharmaceuticals, major reagents, reagent suppliers and the reagent market related to downstream processing, profiles of key equipment players, key reagent players and key CMO players, drivers and restraints and deals analysis.

Major CMOs offer both upstream and downstream manufacturing functions equally. In addition to manufacturing in biopharmaceutical production, they also offer clinical trials, logistics, packaging, and even marketing. According to industry experts, almost 60% of the CMO market in dominated by manufacturing functions, out of which more than 50% is dominated by the downstream process. GBI research suggests that the CMO market size for downstream processing is set to grow at a Compound Annual Growth Rate (CAGR) of 15.1%, which is more than the growth in the overall CMO biopharmaceutical market.

Scope

- A detailed overview of the downstream processing, CMO industry and reagent market.
- Annualized market data and forecasts for the downstream processing, CMO industry and reagent market.
- A detailed overview of key reasons behind outsourcing, outsourcing service models and key drivers and restraints of the market.
- A detailed discussion of the downstream processing.
- Company profiles of major equipments suppliers, CMOs and reagent players including the key services offered by them and their financial information.
- Analysis of the Merger and Acquisition (M&A) deals involving key companies

Reasons to buy

- Develop market-entry and market expansion strategies by identifying areas for high growth and opportunities.
- Understand the factors shaping the downstream processing, CMO industry and reagent market.
- Identify the top players in the major equipment suppliers, CMO and reagent market, their financial revenues, geographical presence and key services offered.
- Analyze the key geographies that are lucrative markets for the downstream processing and as well as CMOs.
- Analyze the trends in licensing and M&A deals and explore potential investment opportunities
- Understand upcoming trends that are poised to drive the future growth of the downstream processing

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

Site License

Site License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.

Corporate License

Corporate License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£2,169.71

Change Currency

GBP EURO USD

Change Currency

GBP
USD

Visitor Comments

All posts are pre-moderated and must obey the house rules.

Change Currency

GBP
USD

Use our research skills: Get free support

Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support

eBrandPromote: Get your brands ranked highly online

eBrandPromote: Let us promote your brand online through article writing, press release distribution, social media and search engine marketing services. Click here to download our eBrandPromote brochure.

Accessibility
Close

Contrast settings

Text size settings